Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.58 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | GPR4 | P46093 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453585 | 0.89 | KCNA5 (0.62) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL19479118 | 0.89 | DRD3 (0.70) | HRH2HRH1KCNA5DRD3DRD2 | |
| SCHEMBL20423457 | 0.89 | DRD3 (0.55) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL29716350 | 0.88 | LTA4H (0.56) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL23301374 | 0.88 | DRD3 (0.54) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL6034847 | 0.88 | HRH2 (0.61) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL14453658 | 0.88 | DRD3 (0.54) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL18135536 | 0.87 | KCNA5 (0.64) | KCNA5DRD3EPHX2LTA4HDRD2 | |
| SCHEMBL25747712 | 0.86 | GPR4 (0.56) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL14453657 | 0.85 | DRD3 (0.52) | HRH2HRH1KCNA5DRD3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988902-B1 | PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221607-A1 | Piperazine Derivatives | SIGMAR1, OPRL1, OPRK1 | HRH2 113/4885HRH1 85/4885KCNA5 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.